On May 25, 2020 Nail Imune Biotech Co., Ltd. (Location: Minato-ku, Tokyo, hereinafter "Noil Imune") and C4U Co., Ltd. (Location: Suita, Osaka Prefecture, hereinafter "C4U") are now editing the next-generation genome of C4U (Press release, Noile-Immune Biotech, MAY 25, 2020, View Source [SID1234561509]). Combining the CRISPR/Cas3 technology, which is a technology, with the PRIME (Proliferation inducing and migration enhancing) technology for adapting genetically modified immune cell therapies such as CAR-T and TCR-T possessed by Noil Imune to solid cancer We would like to inform you that we have signed an agreement for joint research and commercialization of cross-type allogeneic genetically modified immune cell therapy technology.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The CRISPR/Cas3 technology, which is the basic technology of C4U, is the research result of Prof. Tomoshi Mashita of the Institute of Medical Science, University of Tokyo, who is the founding member of C4U and advisor of science and technology, and Professor Junji Takeda of the Institute of Microbial Diseases, Osaka University. A new genome editing technology using the CRISPR/Cas3 system developed based on It is a technology that can counter the CRISPR/Cas9 system, which is currently being researched all over the world, and is attracting attention as a promising genome editing technology that is not affected by the complicated patent situation regarding Cas9.
In addition, PRIME technology, which is the basic technology of Noyle Immune, is the scientific founder and director of Noyle Immune, and Professor Koji Tamada of the Graduate School of Medicine, Yamaguchi University (Professor, Gene and Cell Therapy Center, Institute of Medical Science, University of Tokyo). It is a technology related to cancer immune cell therapy such as CAR-T developed by et al. CAR-T is a technology that not only enhances the functions of CAR-T, etc. by producing cytokines and chemokines, but also causes cancer injury by cancer patients’ own endogenous immune cells.
"I am very pleased to be able to form a business alliance with C4U, which has excellent genome editing technology of its own." In this project, we will combine the PRIME CAR-T technology of Noil Imune and the genome editing technology of C4U. By combining these, we will promote the development of highly active CAR-T cells that utilize immune cells derived from alleles.The combination of domestic technologies is highly versatile and can exert therapeutic effects even on solid cancers. We hope that next-generation CAR-T cells will be developed and a treatment method that will save more patients will be created.This project is based on the Ministry of Education, Culture, Sports, Science and Technology subsidy project "Regional Innovation Ecosystem Formation Program". We are aiming to develop the world’s most advanced cancer immunotherapy with the help of various researches including the beginning."
In addition, C4U’s Satoshi Mashita said, "The PRIME CAR-T technology possessed by Noyle Imune is a wonderful technology that can be proud of in the world, which has successfully overcome the effects of CAR-T cells on solid cancer, which was a weak point, and the sustainability of the effects. By adding our newly developed CRISPR/Cas3 genome editing technology to this technology, it is possible to achieve a more inexpensive, more effective and superior allogeneic CAR-T cell therapy compared to the existing CAR-T cell therapy. I am confident that we will be able to provide to many suffering patients."
Neil Imune and C4U will collaborate on allogeneic genetically modified immune cell therapy under this partnership. Neil Imune will bear part of the costs necessary to carry out this joint research. In addition, both companies have the right to commercialize the results obtained by this joint research, and the right to mutually receive royalties based on the contract. Noil Imune will pay the access fee for the basic technology of C4U when commercializing. Further details of the contract are not disclosed.